Silvia D’Alessio

Dr. Silvia D’Alessio

Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20090 Milan, Italy

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2015 in Gastroenterology
Verified
Journal Article
Closed access
CTCarlotta Tacconi
Carlotta Tacconi
CCCarmen Correale
Carmen Correale
AGAlessandro Gandelli
Alessandro Gandelli
ASAntonino Spinelli
Antonino Spinelli
EDElisabetta Dejana
Elisabetta Dejana
SDSilvio Danese
Silvio Danese

25 September 2018 in Gut Microbes
Verified
Journal Article
Closed access
FUFederica Ungaro
Federica Ungaro
LMLuca Massimino
Luca Massimino
FFFederica Furfaro
Federica Furfaro
VRValeria Rimoldi
Valeria Rimoldi
Laurent Peyrin-birouletLaurent Peyrin-biroulet
Laurent Peyrin-biroulet
SDSilvio Danese
Silvio Danese
Intestinal dysbiosis is one of the causes underlying the pathogenesis of inflammatory bowel disease (IBD), encompassing ulcerative colitis (UC) and Crohn's disease (CD). Besides bacteria, microbiota comprises both prokaryotic and eukaryotic viruses, that together compose the gut virome. Few works have defined the viral composition of stools, while the virome populating intestinal mucosae from early-diagnosed IBD patients has never been studied. Here we show that, by in-depth metagenomic analysis of RNA-Seq data obtained from gut mucosae of young treatment-naïve patients, early-diagnosed for CD and UC, and from healthy subjects (Ctrl), UC patients display significantly higher levels of eukaryotic Hepadnaviridae transcripts by comparison with both Ctrl and CD patients, whereas CD patients show increased abundance of Hepeviridae versus Ctrl. Moreover, we found that UC gut mucosa is characterized by lower levels of Polydnaviridae and Tymoviridae, whereas the mucosa of patients with CD showed a reduced abundance of Virgaviridae. Our findings support the idea that certain eukaryotic viruses might trigger intestinal inflammation and contribute to IBD pathogenesis and pave the way not only for the discovery of novel diagnostic biomarkers but also for the development of anti-viral drugs for the treatment of IBD.

Verified
Journal Article
Open access
PDF file
Marco SpadacciniMarco Spadaccini
Marco Spadaccini
SDSilvia D’Alessio
Silvia D’Alessio
Laurent Peyrin-birouletLaurent Peyrin-biroulet
Laurent Peyrin-biroulet
SDSilvio Danese
Silvio Danese
Background. In the last few decades, a better knowledge of the inflammatory pathways involved in the pathogenesis of Inflammatory Bowel Disease (IBD) has promoted biological therapy as an important tool to treat IBD patients. However, in spite of a wider spectrum of biological drugs, a significant proportion of patients is unaffected by or lose their response to these compounds, along with increased risks of infections and malignancies. For these reasons there is an urgent need to look for new pharmacological targets. The novel Phosphodiesterase 4 (PDE4) inhibitors have been recently introduced as new modulators of intracellular signals and gene transcription for the treatment of IBD. Aim. To discuss and describe the state of the art of this new class of compounds in the IBD field, with particular attention to apremilast. Methods. Published articles selected from PubMed were comprehensively reviewed, with key words including apremilast, inflammatory disease, IBD, psoriasis, psoriatic arthritis, pathogenesis, therapies, and treatment. Results. PDE4 inhibitors generate elevated intracellular levels of cyclic Adenosine Monophosphate (cAMP), that consequently down-regulate the release of pro-inflammatory cytokines in the mucosa of IBD patients. The newly developed apremilast is one of these drugs and has already been approved for the treatment of dermatologic/rheumatologic inflammatory conditions; studies in psoriasis and psoriatic arthritis have in fact demonstrated its clinical activity. However, no clinical trials have yet been published on the use of apremilast in IBD. Conclusion. In light of the similarity of pro-inflammatory signaling pathways across the gut, the skin, and joints, apremilast is likely supposed to show its efficacy also in IBD.

23 October 2017 in Frontiers in Immunology
Verified
Journal Article
Open access
FUFederica Ungaro
Federica Ungaro
FRFederica Rubbino
Federica Rubbino
SDSilvio Danese
Silvio Danese
SDSilvia D’Alessio
Silvia D’Alessio
In the last few decades, the pathogenesis of Inflammatory Bowel Disease (IBD) in genetically predisposed subjects susceptible to specific environmental factors, has been attributed to disturbance of both the immune and non-immune system and/or to the imbalanced interactions with microbes. However, increasing evidences support the idea that defects in pro-resolving pathways might strongly contribute to IBD onset. The resolution of inflammation is now recognized as a dynamic event coordinated by specialized pro-resolving lipid mediators, which dampen inflammation-sustaining events, such as angiogenesis, release of pro-inflammatory cytokines, clearance of apoptotic cells and microorganisms. Among these pro-resolving molecules, those derived from essential polyunsaturated fatty acids (PUFAs) have been shown to induce favorable effects on a plethora of human inflammatory disorders, including IBD. Here we offer a summary of mechanisms involving both cellular and molecular components of the immune response and underlying the anti-inflammatory and pro-resolving properties of PUFAs and their derivatives in the gut, focusing on both ω-3 and ω-6 lipid mediators. These fatty acids may influence IBD progression by: reducing neutrophil transmigration across the intestinal vasculature and the epithelium, preventing the release of pro-inflammatory cytokines and the up-regulation of adhesion molecules, and finally by promoting the production of other pro-resolving molecules. We also discuss the numerous attempts in using pro-resolving PUFAs to ameliorate intestinal inflammation, both in patients with IBD and mouse models. Although their effects in reducing inflammation is incontestable, results from previous works describing the effects of PUFA administration to prevent or treat IBD are controversial. Therefore, more efforts are needed not only to identify and explain the physiological functions of PUFAs in the gut, but also to unveil novel biosynthetic pathways of these pro-resolving lipid mediators that may be dysregulated in these gut-related disorders. We suppose that either PUFAs or new medications specifically promoting resolution-regulating mediators and pathways will be much better tolerated by patients with IBD, with the advantage of avoiding immune suppression.

1 November 2017 in Gastroenterology
Verified
Journal Article
Closed access
FUFederica Ungaro
Federica Ungaro
CTCarlotta Tacconi
Carlotta Tacconi
LMLuca Massimino
Luca Massimino
PCPaola Antonia Corsetto
Paola Antonia Corsetto
CCCarmen Correale
Carmen Correale
SDSilvio Danese
Silvio Danese

19 March 2019 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
FUFederica Ungaro
Federica Ungaro
PCPiergiuseppe Colombo
Piergiuseppe Colombo
LMLuca Massimino
Luca Massimino
GUGiovanni Stefano Ugolini
Giovanni Stefano Ugolini
CCCarmen Correale
Carmen Correale
SDSilvia D’Alessio
Silvia D’Alessio